XSHG600252
Market cap1.08bUSD
Jan 14, Last price
2.36CNY
1D
3.06%
1Q
5.36%
Jan 2017
-48.47%
Name
Guangxi Wuzhou Zhongheng Group Co.
Chart & Performance
Profile
Guangxi Wuzhou Zhongheng Group Co., Ltd. researches, develops, manufactures, and sells pharmaceuticals in China. The company offers pills, capsules, and injections and tablets for cardiovascular and cerebrovascular diseases, bruises, gynecological diseases, and respiratory diseases. It also produces health food products under the DOUBLE MONEY brand, as well as health-care functional beverages, smokable turtle pastes, jelly-type turtle paste, etc. The company is based in Wuzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 3,096,542 14.10% | 2,713,770 -14.17% | |||||||
Cost of revenue | 2,816,978 | 2,429,893 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 279,564 | 283,877 | |||||||
NOPBT Margin | 9.03% | 10.46% | |||||||
Operating Taxes | 52,227 | 51,417 | |||||||
Tax Rate | 18.68% | 18.11% | |||||||
NOPAT | 227,337 | 232,460 | |||||||
Net income | 84,309 580.48% | 12,390 -92.85% | |||||||
Dividends | (107,390) | (92,481) | |||||||
Dividend yield | 1.25% | 1.03% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 1,028,342 | 1,314,763 | |||||||
Long-term debt | 564,698 | 666,298 | |||||||
Deferred revenue | 170,673 | 173,084 | |||||||
Other long-term liabilities | 73,936 | 16,100 | |||||||
Net debt | (3,357,623) | (3,293,338) | |||||||
Cash flow | |||||||||
Cash from operating activities | 484,100 | ||||||||
CAPEX | (166,925) | ||||||||
Cash from investing activities | (812,051) | 253,324 | |||||||
Cash from financing activities | (290,824) | 329,032 | |||||||
FCF | 6,541 | 51,860 | |||||||
Balance | |||||||||
Cash | 3,590,094 | 4,200,297 | |||||||
Long term investments | 1,360,569 | 1,074,102 | |||||||
Excess cash | 4,795,836 | 5,138,710 | |||||||
Stockholders' equity | 7,499,801 | 8,378,106 | |||||||
Invested Capital | 5,307,403 | 5,231,796 | |||||||
ROIC | 4.31% | 4.21% | |||||||
ROCE | 2.75% | 2.73% | |||||||
EV | |||||||||
Common stock shares outstanding | 3,427,187 | 3,425,209 | |||||||
Price | 2.51 -4.56% | 2.63 -31.87% | |||||||
Market cap | 8,602,238 -4.51% | 9,008,299 -31.87% | |||||||
EV | 6,951,980 | 7,486,634 | |||||||
EBITDA | 456,624 | 473,633 | |||||||
EV/EBITDA | 15.22 | 15.81 | |||||||
Interest | 65,525 | 81,912 | |||||||
Interest/NOPBT | 23.44% | 28.85% |